Anthony Comerota (Alexandria, USA), global principal investigator of the VIVO trial, discusses the highlights of the 12-month results of the VIVO clinical study that were presented at VIVA 2020.
While the safety and efficacy of the Zilver Vena stent, which recently received US FDA 510(k) clearance, were “excellent”, Comerota highlights the need for three-year and indeed, much longer-term evidence. He notes that patients with symptomatic iliofemoral venous outflow obstruction, who are receiving these implants are, on average, a population with a long life expectancy.
